Researchers from the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), have identified a promising antiviral compound that can inhibit a range of enteroviruses, including Enterovirus D68 (EV-D68), an emerging respiratory virus linked to severe respiratory illness and acute flaccid myelitis, a condition that can cause paralysis.

A study led by Flinders University and published in the Australian and New Zealand Journal of Obstetrics and Gynaecology found requests by GPs for anti-Müllerian hormone (AMH) tests increased more than 13-fold between 2011 and 2021, despite growing evidence that the test cannot predict whether a woman will become pregnant naturally - not now or in the future.

Insilico Medicine (“Insilico,” HKEX: 3696), a clinical-stage biotechnology company powered by generative AI, today announced that it has dosed the first patient with Rentosertib (known as ISM001-055 / INS018_055) in GENESIS-IPF-3, a Phase III clinical trial (NCT07687459, CTR20262475) at Peking Union Medical College Hospital, while Shanghai Pulmonary Hospital has also enrolled its first patient on the same day.

Artificial intelligence (AI) is increasingly integrated in public health for disease surveillance, behavioral interventions, risk communication, and population health management. However, fragmented oversight and limited equity safeguards can allow AI systems to reinforce existing disparities and create new risks for marginalized populations. A recent analytical essay examines these challenges and outlines strategies for responsible AI use, including equity assessments, community-based validation, transparency, data sovereignty, and human oversight.